GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All conditions

GLP-1 Therapy for PCOS in India — What the Evidence Shows

Last reviewed 12 May 2026 · Indian guideline context

The short answer

GLP-1 therapies (semaglutide, tirzepatide) can support PCOS management in India when used for the licensed indication of obesity — typically BMI ≥27.5 with PCOS as a metabolic comorbidity. Evidence shows meaningful improvement in insulin resistance, menstrual regularity, and weight in trials, but GLP-1 is not directly approved as a PCOS treatment. Always combine with a gynaecologist + endocrinologist team. Take the 5-min eligibility check.

See if you’re a candidate

The 5-minute Indian-guideline eligibility check factors in your PCOS status.

Take the free assessment →

PCOS in India — the context

PCOS affects an estimated 10-22% of reproductive-age women in India (varying by diagnostic criteria), with significantly higher prevalence in urban populations. Insulin resistance is present in 50-70% of Indian PCOS cases regardless of BMI. The "lean PCOS" phenotype is more common in Indian women than in Western populations, which makes the BMI-only eligibility threshold for GLP-1 less straightforward — many lean PCOS patients have metabolically obese profiles (waist circumference ≥80 cm, insulin resistance, dyslipidemia) that still benefit from GLP-1 therapy under physician judgment.

How GLP-1 helps — mechanism + evidence

GLP-1 receptor agonists improve insulin sensitivity, reduce hyperinsulinemia (a key PCOS driver), promote weight loss, and have shown improvements in androgen levels and menstrual regularity in published trials. The clinical evidence base specifically for PCOS is growing but not yet large enough for a formal PCOS indication. In India, prescribing is for the obesity indication (Wegovy, Mounjaro) with PCOS as a comorbidity, or off-label use of Ozempic. Indian endocrinology and gynaecology societies have begun acknowledging GLP-1 as a relevant tool in obesity-associated PCOS.

Key trials

  • Jensterle et al. 2020: Semaglutide vs metformin in PCOS — semaglutide group showed greater weight loss and improvement in insulin resistance markers.
  • STEP 1: Semaglutide 2.4 mg (Wegovy dose) achieved mean 14.9% weight reduction vs 2.4% placebo over 68 weeks in adults with obesity — population included women with PCOS-spectrum metabolic profiles.
  • Salamun et al. 2018: Liraglutide in obese PCOS patients improved menstrual frequency and reduced free testosterone.
  • SURMOUNT-1: Tirzepatide achieved up to 22.5% weight reduction at 72 weeks — strongest weight-loss outcome among GLP-1-class therapies relevant to PCOS comorbid obesity.

Eligibility — who fits?

Indian-guideline eligibility for GLP-1 in PCOS typically requires BMI ≥27.5 (or ≥25 with metabolic comorbidities). The 5-minute GLP-1 Check assessment factors in PCOS status, insulin resistance markers, waist circumference, and current symptoms (irregular cycles, hirsutism, acne) to map your fit. For lean PCOS patients (BMI <25 with strong insulin resistance), the decision is more nuanced and requires direct specialist judgment.

Indian-context considerations

  • •PCOS patients often have concurrent fertility goals — discuss timing of any planned conception with your specialist; GLP-1 is contraindicated during pregnancy and should be discontinued 2 months before planned conception
  • •PCOS + Indian diet (rice-heavy, refined carbs, late dinners) — pair GLP-1 with low-glycaemic dietary changes for best results
  • •Hirsutism and acne improvements are typically secondary outcomes from weight loss + insulin sensitivity rather than direct anti-androgen effects
  • •Concurrent metformin is often continued alongside GLP-1 in PCOS — discuss dosing with your endocrinologist
  • •Mental health comorbidities (depression, anxiety) are common in PCOS — discuss with your physician before starting GLP-1

Brand options for PCOS

Wegovy

On-label for obesity at BMI ≥27.5 with comorbidity (PCOS metabolic syndrome qualifies). Strongest evidence base for the 2.4 mg dose.

Mounjaro

Strongest weight-loss outcomes (SURMOUNT trials) — meaningful for PCOS where weight loss is a primary lever for restoring metabolic + reproductive function.

Indian generic semaglutide (Sundae, Noveltreat, Obeda)

Cost-effective option (₹1,290–3,500/month) for sustained therapy when innovator brands stretch budget.

Full brand catalog: Semaglutide brands in India → · India pricing →

Patient pathway

Typical pathway: (1) take the 5-minute GLP-1 Check assessment to map fit; (2) book a combined endocrinology + gynaecology consult (or sequential — endo first, then gynaec); (3) baseline labs (HbA1c, fasting insulin, lipid profile, AMH, testosterone, ultrasound); (4) discuss therapy options including GLP-1 + concurrent PCOS management (lifestyle, metformin, oral contraceptives where appropriate); (5) start titration with monthly follow-ups for the first 4-6 months, tracking weight, menstrual pattern, and symptom changes.

Frequently asked questions

Is Ozempic FDA-approved or DCGI-approved for PCOS in India?+
No. Ozempic is approved by DCGI for type 2 diabetes only. Wegovy is approved for obesity. Neither has a direct PCOS indication. PCOS prescribing typically happens under the obesity indication (Wegovy, Mounjaro) when BMI criteria are met, with PCOS noted as a metabolic comorbidity.
Can lean PCOS patients (BMI <25) take GLP-1 therapy?+
It is more nuanced. Indian guideline BMI thresholds for GLP-1 are ≥25 with comorbidity or ≥27.5 absolute. Lean PCOS patients with strong insulin resistance, elevated waist circumference, or family history may still be candidates under direct specialist judgment, but the formal labeling does not cover this case. Discuss with your endocrinologist.
Will GLP-1 help me get pregnant if I have PCOS?+
Indirectly. By improving insulin sensitivity and supporting weight loss, GLP-1 can restore ovulation in some PCOS patients. However, GLP-1 itself is contraindicated during pregnancy. The recommended path is GLP-1 → weight + metabolic improvement → discontinue GLP-1 (2-month washout) → attempt conception. Discuss timing with your gynaecologist.
How much weight can I expect to lose with GLP-1 for PCOS?+
Average weight loss in published trials: ~15% with semaglutide 2.4 mg (Wegovy dose) at 68 weeks; ~22% with tirzepatide 15 mg (Mounjaro dose) at 72 weeks. PCOS patients with strong insulin resistance often respond well. Individual outcomes vary widely based on baseline weight, diet, exercise, and concurrent therapies.
Will my hirsutism (excess hair) improve with GLP-1?+
Possibly, but indirectly. Hirsutism improvement in PCOS is driven by reducing androgens, which can happen as a secondary effect of weight loss + insulin sensitivity improvements. Direct anti-androgen effects of GLP-1 are mild. Most patients see noticeable hirsutism reduction only after 6-12 months of sustained therapy, alongside weight loss.
Can I take GLP-1 alongside metformin for PCOS?+
Yes — concurrent GLP-1 + metformin is common in PCOS management and is supported by evidence. Both improve insulin sensitivity through different mechanisms. Your endocrinologist will determine the optimal dose combination. Side effects (GI upset) may overlap during titration, so dose adjustments are often needed.
What does GLP-1 therapy for PCOS cost monthly in India?+
Innovator brands: Wegovy ₹5,660–16,400/month, Mounjaro ₹14,000–27,500/month. Indian generic semaglutides (Sundae, Noveltreat, Obeda, Semaglyn): ₹1,290–3,500/month. Total monthly cost including specialist consults, labs, and medication typically ranges ₹3,500–32,000 depending on brand choice and consult frequency.

Related conditions

Type 2 Diabetes

GLP-1 for Type 2 Diabetes — Indian context

Prediabetes

GLP-1 for Prediabetes — Indian context

Fatty Liver (NAFLD/MASLD)

GLP-1 for Fatty Liver (NAFLD/MASLD) — Indian context

See if GLP-1 fits your PCOS profile

5 minutes. Uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Take the free assessment →

Educational content based on DCGI-approved labelling, peer-reviewed trials, RSSDI/ESI/INASL Indian clinical guidelines, and published literature. Not a substitute for a doctor’s clinical judgment. GLP-1 therapies are Schedule H drugs in India and require a doctor’s prescription. Always consult a qualified medical practitioner before starting any therapy.